No Data
HOB Biotech GroupLtd's (SHSE:688656) Shareholders Have More To Worry About Than Only Soft Earnings
bocom intl: sino biopharm's 3Q24 performance exceeded expectations, acquiring the controlling rights of the first A-share company.
Bocom Intl released a research report stating that sino biopharm (01177) 3Q24 revenue increased by 14.3% year-on-year to 5.47 billion yuan, with adjusted net income increasing by 58.0% to 0.6 billion yuan, both exceeding the bank's expectations. Management maintains the guidance of double-digit revenue growth for the full year. In addition, the company acquired control of Hoauoboo (688656.SH), entering the immune diagnostic track, with an acquisition price of 33.74 yuan/share. After completion, Hoauoboo will become the first subsidiary of sino biopharm listed on the A-share market. The bank believes that its product portfolio will complement the company in the fields of respiratory, autoimmune, and other diseases.
STAR Evening News | Hao Europe Borg Holdings' shareholder control changes, stocks to resume trading tomorrow, Suzhou Veichi Electric plans to establish Asia Vets robot&automation project
1. As an electric autos company, BYD Company Limited's quarterly revenue exceeded Tesla for the first time; 2. Six departments: promoting the installation of photovoltaic systems on existing building roofs; 3. Three departments: supporting the IPO financing of relevant enterprises that meet the conditions of new materials big datacenter.
Sino Biopharm (01177.HK) plans to acquire 29.99% equity of Haohua Bo (688656.SH) and intends to make a voluntary partial tender offer to acquire up to 25.01% equity of Haohua Bo.
Grain Alliance reported on October 30th that sino biopharm (01177.HK) announced that on October 30, 2024, including, its indirectly wholly-owned subsidiary Peking Run Kang and Huarixiangtian Biotechnology Hong Kong entered into an equity transfer agreement, whereby Peking Run Kang agreed to acquire and Huarixiangtian Biotechnology Hong Kong agreed to sell its holdings in the target company. As of the date of this announcement, Huarixiangtian Biotechnology Hong Kong holds a total of 56.38% equity in Hao Obo (688656.SH). After the completion of the equity transfer, (i) Peking Run Kang will hold 29.99% of the target company's equity; and (ii) concerted action.
Haoubo: Jiangsu Haoubo Biomedical Co., Ltd. Report for the third quarter of 2024
Jiangsu Haoubo Biomedical Co., Ltd. Report for the Third Quarter of 2024
HOB Biotech Group Corp.,Ltd (SHSE:688656) Shares May Have Slumped 28% But Getting In Cheap Is Still UnlikelyNo Data
No Data
